tert-butyl (2S)-1-((2S)-2-amino-3-methylbutanoyl)pyrrolidine-2-carboxylate hydrochloride

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (2S)-1-((2S)-2-amino-3-methylbutanoyl)pyrrolidine-2-carboxylate hydrochloride
• 英文别名: H-Val-Pro-OtBu hydrochloride；H-Val-Pro-OtBu . HCl；tert-butyl (2S)-1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidine-2-carboxylate;hydrochloride
• 化学式: C₁₄H₂₆N₂O₃*ClH
• 分子量: 306.833
• InChiKey: AFLLLGQZFVJBBK-ACMTZBLWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.72
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (2S)-1-((2S)-2-amino-3-methylbutanoyl)pyrrolidine-2-carboxylate hydrochloride 在 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.5h， 生成 {(2S)-1-[(2S)-3-methyl-2-(methylsulfonamido)butanoyl]pyrrolidine-2-yl}-N-{(1S)-2-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-2-hydroxy-1-(methylethyl)ethyl}carboxamide
  参考文献：
  名称：

  Development of Orally Active Nonpeptidic Inhibitors of Human Neutrophil Elastase

  摘要：

  5-Amino-2-phenylpyrimidin-6-ones, some of their desamino derivatives, and miscellaneous derivatives were synthesized and biologically evaluated on both in vitro activity and oral activity in an acute hemorrhagic assay. These compounds contained an alpha -keto-1,3,4-oxadiazole moiety to bind covalently to the Ser-195 hydroxy group of human neutrophil elastase (HNE). Among those tested, compounds 11a-c,e,i-1(F), 11d,e,k(H), ald,e,k(F), and ald,e(H) showed a good oral profile. RS-Mixture 3(H) was selected for clinical evaluation based on its oral potency, duration of action, enzyme selectivity, safety profile, and ease of synthesis. Structure-activity relationships (SARs) are discussed.

  DOI：

  10.1021/jm000410y

文献信息

• Synthesis of <i>S</i>-Linked Glycopeptides in Aqueous Solution
  作者：Xiangming Zhu、Kandasamy Pachamuthu、Richard R. Schmidt

  DOI：10.1021/jo034148n

  日期：2003.7.1

  the peptide moiety, mixtures of DMF and water could be employed for successfully carrying out this reaction. Thus, S-glycosylated tripeptides 42-45 could be obtained. Combination of this method with chemical ligation was also successfully carried out.

  在碳酸钠作为碱存在下，在两相条件下，用O-乙酰基保护的糖基卤化物对高半胱氨酸和含半胱氨酸的肽进行直接S-糖基化的研究取得了优异的结果。因此，分别从葡糖基溴化物，半乳糖基溴化物，乳糖基溴化物，唾液酸氯和N-Troc保护的2-氨基-2-脱氧葡糖基溴化物S-糖基化的二肽分别为15、18-21、23、24和26-29。以优异的产量获得。或者，取决于肽部分的溶解度，可以使用DMF和水的混合物来成功地进行该反应。因此，可以获得S-糖基化的三肽42-45。该方法与化学连接的结合也已成功进行。
• [EN] PRODRUGS CLEAVABLE BY CD26<br/>[FR] PROMEDICAMENTS POUVANT ETRE CLIVES A MOYEN DE CD26
  申请人：LEUVEN K U RES & DEV

  公开号：WO2004098644A1

  公开（公告）日：2004-11-18

  The present invention provides a new prodrug technology and new prodrugs in order to increase the solubility, to modulate plasma protein binding or to enhance the biovailability of a drug. In the present invention the prodrugs are conjugates of a therapeutic compound and a peptide (eg tetrapeptide or hexapeptide) wherein the conjugate is cleavable by dipeptidyl-peptidases, more preferably by CD26, also known as DPPIV (dipeptidyl aminodipeptidase IV). The present invention furthermore provides a method of producing said prodrugs, to enhance brain and lymphatic delivery of drugs and/or to extend drug half-lives in plasma.

  本发明提供了一种新的前药技术和新的前药，以增加药物的溶解度，调节血浆蛋白结合或增强药物的生物利用度。在本发明中，前药是治疗化合物和肽（例如四肽或六肽）的结合物，其中结合物可被二肽肽酶（更优选为CD26，也称为DPPIV，即二肽氨二肽酶IV）水解。本发明还提供了一种生产所述前药的方法，以增强药物在大脑和淋巴系统中的传递，并/或延长药物在血浆中的半衰期。
• Prodrugs Cleavable by Cd26
  申请人：Balzarini Jan

  公开号：US20070275900A1

  公开（公告）日：2007-11-29

  The present invention provides a new prodrug technology and new prodrugs in order to increase the solubility, to modulate plasma protein binding or to enhance the biovailability of a drug. In the present invention the prodrugs are conjugates of a therapeutic compound and a peptide (eg tetrapeptide or hexapeptide) wherein the conjugate is cleavable by dipeptidyl-peptidases, more preferably by CD26, also known as DPPIV (dipeptidyl aminodipeptidase IV). The present invention furthermore provides a method of producing said prodrugs, to enhance brain and lymphatic delivery of drugs and/or to extend drug half-lives in plasma.

  本发明提供了一种新的前药技术和新的前药，以增加药物的溶解度，调节血浆蛋白结合或增强药物的生物利用度。在本发明中，前药是治疗化合物和肽（例如四肽或六肽）的结合物，其中结合物可被二肽基-肽酶（更好地是CD26，也称为DPPIV（二肽基氨肽酰二肽酶IV））水解。本发明还提供了一种生产所述前药的方法，以增强药物在脑和淋巴中的递送和/或延长药物在血浆中的半衰期。
• Prodrugs cleavable by CD26
  申请人：Consejo Superior de Investigaciones Clentificas (CSIC)

  公开号：US08236756B2

  公开（公告）日：2012-08-07

  The present invention provides a new prodrug technology and new prodrugs in order to increase the solubility, to modulate plasma protein binding or to enhance the biovailability of a drug. In the present invention the prodrugs are conjugates of a therapeutic compound and a peptide (eg tetrapeptide or hexapeptide) wherein the conjugate is cleavable by dipeptidyl-peptidases, more preferably by CD26, also known as DPPIV (dipeptidyl aminodipeptidase IV). The present invention furthermore provides a method of producing the prodrugs, to enhance brain and lymphatic delivery of drugs and/or to extend drug half-lives in plasma.

  本发明提供了一种新的前药技术和新的前药，以增加药物的溶解度，调节血浆蛋白结合或增强药物的生物利用度。在本发明中，前药是治疗化合物和肽（例如四肽或六肽）的结合物，其中结合物可被二肽基肽酶（更偏好地为CD26，也称为DPPIV（二肽氨二肽酶IV））水解。本发明还提供了一种制备前药的方法，以增强药物在脑和淋巴系统中的输送和/或延长药物在血浆中的半衰期。
• Development of Orally Active Nonpeptidic Inhibitors of Human Neutrophil Elastase
  作者：Kazuyuki Ohmoto、Tetsuya Yamamoto、Motohiro Okuma、Toshihide Horiuchi、Hirotoshi Imanishi、Yoshihiko Odagaki、Kazuhito Kawabata、Tomohiko Sekioka、Yasushi Hirota、Shozo Matsuoka、Hisao Nakai、Masaaki Toda、John C. Cheronis、Lyle W. Spruce、Albert Gyorkos、Maciej Wieczorek

  DOI：10.1021/jm000410y

  日期：2001.4.1

  5-Amino-2-phenylpyrimidin-6-ones, some of their desamino derivatives, and miscellaneous derivatives were synthesized and biologically evaluated on both in vitro activity and oral activity in an acute hemorrhagic assay. These compounds contained an alpha -keto-1,3,4-oxadiazole moiety to bind covalently to the Ser-195 hydroxy group of human neutrophil elastase (HNE). Among those tested, compounds 11a-c,e,i-1(F), 11d,e,k(H), ald,e,k(F), and ald,e(H) showed a good oral profile. RS-Mixture 3(H) was selected for clinical evaluation based on its oral potency, duration of action, enzyme selectivity, safety profile, and ease of synthesis. Structure-activity relationships (SARs) are discussed.